Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Hodgkin Disease 9Neoplasms 3Melanoma 3Uveal Melanoma 1Melanoma, Cutaneous Malignant 1Lung Neoplasms 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Kidney Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Advanced Melanoma 1

Interventions

Oxaliplatin 14Leucovorin 12Fluorouracil 12Cetuximab 10Bevacizumab 9pembrolizumab 7Specimen Handling 7Nivolumab 6Magnetic Resonance Spectroscopy 6Irinotecan 5encorafenib 4Pemetrexed 4Gemcitabine 4Cisplatin 4fludarabine 3cemiplimab 3Laparoscopy 3Folfox protocol 3Early Intervention, Educational 3Cyclophosphamide 3Carboplatin 3Capecitabine 3Biopsy 3trifluridine tipiracil drug combination 2pertuzumab 2durvalumab 2dehydroftorafur 2aldesleukin 2X-Rays 2Watchful Waiting 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × Dacarbazine × 90 days × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡